Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404209 | 1.00 | HKDC1 (0.55) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL29506909 | 0.91 | HKDC1 (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL881251 | 0.91 | HKDC1 (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL5839502 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL29723632 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL29882877 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL17207742 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL12562236 | 0.86 | HKDC1 (0.46) | HKDC1TOP2AAGTR1RAB9AKDM4E | |
| SCHEMBL9938958 | 0.85 | HKDC1 (0.54) | HKDC1TOP2AAGTR1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL9938465 | 0.84 | HKDC1 (0.53) | HKDC1TOP2AAGTR1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118217419-B | Nanometer drug delivery system for overcoming tumor multidrug resistance and preparation method thereof | 山东理工大学 | 2024-08-20 | — | — | CN | claimed |
| CN-118217419-A | Nanometer drug delivery system for overcoming tumor multidrug resistance and preparation method thereof | 山东理工大学 | 2024-06-21 | — | — | CN | claimed |
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | claimed |
| US-10012659-B2 | Methods for diagnosing iron-related pathologies | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-07-03 | — | — | US | claimed |
| EP-2945629-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | ONCOCHEL THERAPEUTICS LLC (US) | 2015-11-25 | — | — | EP | claimed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | claimed |
| WO-2014078898-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | claimed |
| EP-2453892-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATING CANCER | INST NAT SANTE RECH MED (FR) | 2013-05-29 | — | — | EP | claimed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | claimed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010000008-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2010-01-07 | — | — | WO | disclosed |
| EP-1608623-A4 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | RICHARDSON, DESI (AU) | 2006-11-09 | — | — | US | disclosed |
| EP-1608623-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004069801-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | ABCC1, SLC47A1, ABCB1 | HKDC1 539/4885TOP2A 152/4885AGTR1 1610/4885 |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | SLC40A1, SLC30A6, SLC39A3 | HKDC1 2582/4885TOP2A 641/4885AGTR1 2794/4885 |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | HKDC1 2923/4885TOP2A 4853/4885AGTR1 200/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | HKDC1 1295/4885TOP2A 3719/4885AGTR1 1186/4885 |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | HKDC1 402/4885TOP2A 334/4885AGTR1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.